Edition:
United Kingdom

Deena Beasley

Bluebird prices gene therapy at 1.58 million euros over 5 years

14 Jun 2019

Bluebird bio Inc on Friday set a price for its gene therapy, Zynteglo, at 1.58 million euros ($1.78 million) over five years, after winning conditional approval in Europe this month to treat a rare genetic blood disorder.

Bluebird prices gene therapy at 1.575 mln euros over five years

14 Jun 2019

June 14 Bluebird bio Inc on Friday set a price for its gene therapy, Zynteglo, at 1.575 million euros ($1.78 million) over five years, after winning conditional approval in Europe this month to treat a rare genetic blood disorder.

Amgen drug shows high response rate in small lung and colon cancer trial

03 Jun 2019

An experimental Amgen Inc drug that targets a specific genetic mutation significantly reduced tumor size in half of evaluated patients with advanced lung cancer in a small, early-stage trial, researchers said on Monday, sending the U.S. biotechnology company's share up nearly 6 percent.

Amgen drug shows high response rate in small lung and colon cancer trial

03 Jun 2019

June 3 An experimental Amgen Inc drug that targets a specific genetic mutation significantly reduced tumor size in half of evaluated patients with advanced lung cancer in a small, early-stage trial, researchers said on Monday.

Novartis bietet US-Krankenversicherern Rabatt für teure Gentherapie

13 May 2019

Zürich/Los Angeles Der Schweizer Pharmakonzern Novartis bietet Krankenversicherungen in den USA Preisnachlässe für seine neue Gentherapie gegen die Muskelerkrankung SMA.

Exclusive: Novartis pitches discounts on pricey gene therapy for deadly muscle disorder

10 May 2019

LOS ANGELES/ZURICH Novartis AG is offering price discounts in negotiations with U.S. health insurers on its gene therapy for spinal muscular atrophy (SMA), a treatment that could cost more than a million dollars, but the gesture comes with strings attached.

Gilead to separate Kite cell therapy unit, posts higher profit

02 May 2019

Gilead Sciences Inc, which hired Roche veteran Daniel O'Day to be its new chief executive, on Thursday said Kite Pharma, the cancer-focused cell therapy company it acquired in 2017, will become a separate business unit.

Gilead posts higher first-quarter profit; drug sales in line with expectations

02 May 2019

May 2 Gilead Sciences Inc on Thursday reported a higher first-quarter profit as sales of its important HIV and hepatitis C drugs were largely in line with Wall Street estimates.

Amgen revenue flat as migraine, cholesterol drugs miss sales expectations

01 May 2019

Amgen Inc on Tuesday reported first-quarter revenue that was unchanged from a year ago as key drugs, including new migraine treatment Aimovig and cholesterol fighter Repatha, face pricing pressure.

Amgen revenue flat for first quarter, Aimovig, Repatha fall short of sales expectations

30 Apr 2019

April 30 Amgen Inc on Tuesday reported first-quarter revenue that was unchanged from a year ago and net income fell 14 percent as sales of key drugs, including new migraine treatment Aimovig and cholesterol fighter Repatha, face competition and pressure to lower prices.

World News